Loading…

Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter

Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of subst...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2023-04, Vol.385 (1), p.62-75
Main Authors: Kozell, Laura B, Eshleman, Amy J, Swanson, Tracy L, Bloom, Shelley H, Wolfrum, Katherine M, Schmachtenberg, Jennifer L, Olson, Randall J, Janowsky, Aaron, Abbas, Atheir I
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3
cites cdi_FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3
container_end_page 75
container_issue 1
container_start_page 62
container_title The Journal of pharmacology and experimental therapeutics
container_volume 385
creator Kozell, Laura B
Eshleman, Amy J
Swanson, Tracy L
Bloom, Shelley H
Wolfrum, Katherine M
Schmachtenberg, Jennifer L
Olson, Randall J
Janowsky, Aaron
Abbas, Atheir I
description Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT) , 5-HT , and 5-HT receptors (5-HT R, 5-HT R, and 5HT R, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT R, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT R, 5-HT R, and SERT. Sorting by the ratio of 5-HT to 5-HT , 5-HT , or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT Rs versus 5-HT Rs and 5-HT Rs. 5-substituted compounds exhibited high affinities for 5-HT Rs, low affinities for 5-HT Rs, and a range of affinities for 5-HT Rs, resulting in selectivity for 5-HT Rs versus 5-HT Rs but not versus 5-HT Rs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT Rs compared with 5-HT Rs and 5-HT Rs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT Rs in comparison with 5-HT Rs and 5-HT Rs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT) , 5-HT , and 5HT receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT versus 5-HT and 5-HT receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic
doi_str_mv 10.1124/jpet.122.001454
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1124_jpet_122_001454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36669875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3</originalsourceid><addsrcrecordid>eNo9kE1Lw0AURQdRbK2u3cksLZh2PjKTZBmKWqGgtHUdJvOhKU0mTKZi_ok_18TUrt7lcN97cAC4xWiGMQnnu1r7GSZkhhAOWXgGxpgRHCCM6DkYI0RIQBlnI3DVNLu-E3J6CUaUc57EERuDn7dP4Uoh7d5-FBKm0hdfhW-hNXBzyBtf-IPXCm5dW3tRFpVuoPCQBctWOfvd-hOH9x3cTiFJ4VpLXXvrBvRHpg9wyAu4Pkac9lFUCm60s95WRdW9EVVTW-e1uwYXRuwbfXOcE_D-9LhdLIPV6_PLIl0FEqOEBcoIKqiOUBJSlGgVS8MNz6M4QjqMJUcGY4GiWEhF4jDRuclDyQljRNEkMpJOwHy4K51tGqdNVruiFK7NMMp6x1nvOOscZ4PjbuNu2KgPeanVqf8vlf4CaNp1qw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter</title><source>Medical Journals</source><creator>Kozell, Laura B ; Eshleman, Amy J ; Swanson, Tracy L ; Bloom, Shelley H ; Wolfrum, Katherine M ; Schmachtenberg, Jennifer L ; Olson, Randall J ; Janowsky, Aaron ; Abbas, Atheir I</creator><creatorcontrib>Kozell, Laura B ; Eshleman, Amy J ; Swanson, Tracy L ; Bloom, Shelley H ; Wolfrum, Katherine M ; Schmachtenberg, Jennifer L ; Olson, Randall J ; Janowsky, Aaron ; Abbas, Atheir I</creatorcontrib><description>Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT) , 5-HT , and 5-HT receptors (5-HT R, 5-HT R, and 5HT R, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT R, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT R, 5-HT R, and SERT. Sorting by the ratio of 5-HT to 5-HT , 5-HT , or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT Rs versus 5-HT Rs and 5-HT Rs. 5-substituted compounds exhibited high affinities for 5-HT Rs, low affinities for 5-HT Rs, and a range of affinities for 5-HT Rs, resulting in selectivity for 5-HT Rs versus 5-HT Rs but not versus 5-HT Rs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT Rs compared with 5-HT Rs and 5-HT Rs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT Rs in comparison with 5-HT Rs and 5-HT Rs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT) , 5-HT , and 5HT receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT versus 5-HT and 5-HT receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic agents.</description><identifier>ISSN: 0022-3565</identifier><identifier>EISSN: 1521-0103</identifier><identifier>DOI: 10.1124/jpet.122.001454</identifier><identifier>PMID: 36669875</identifier><language>eng</language><publisher>United States</publisher><subject>Hallucinogens ; Humans ; Receptor, Serotonin, 5-HT2A - metabolism ; Receptor, Serotonin, 5-HT2C - metabolism ; Serotonin - metabolism ; Serotonin Plasma Membrane Transport Proteins ; Tryptamines - pharmacology</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2023-04, Vol.385 (1), p.62-75</ispartof><rights>U.S. Government work not protected by U.S. copyright.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3</citedby><cites>FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3</cites><orcidid>0000-0002-7080-3509</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36669875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kozell, Laura B</creatorcontrib><creatorcontrib>Eshleman, Amy J</creatorcontrib><creatorcontrib>Swanson, Tracy L</creatorcontrib><creatorcontrib>Bloom, Shelley H</creatorcontrib><creatorcontrib>Wolfrum, Katherine M</creatorcontrib><creatorcontrib>Schmachtenberg, Jennifer L</creatorcontrib><creatorcontrib>Olson, Randall J</creatorcontrib><creatorcontrib>Janowsky, Aaron</creatorcontrib><creatorcontrib>Abbas, Atheir I</creatorcontrib><title>Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT) , 5-HT , and 5-HT receptors (5-HT R, 5-HT R, and 5HT R, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT R, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT R, 5-HT R, and SERT. Sorting by the ratio of 5-HT to 5-HT , 5-HT , or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT Rs versus 5-HT Rs and 5-HT Rs. 5-substituted compounds exhibited high affinities for 5-HT Rs, low affinities for 5-HT Rs, and a range of affinities for 5-HT Rs, resulting in selectivity for 5-HT Rs versus 5-HT Rs but not versus 5-HT Rs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT Rs compared with 5-HT Rs and 5-HT Rs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT Rs in comparison with 5-HT Rs and 5-HT Rs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT) , 5-HT , and 5HT receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT versus 5-HT and 5-HT receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic agents.</description><subject>Hallucinogens</subject><subject>Humans</subject><subject>Receptor, Serotonin, 5-HT2A - metabolism</subject><subject>Receptor, Serotonin, 5-HT2C - metabolism</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Plasma Membrane Transport Proteins</subject><subject>Tryptamines - pharmacology</subject><issn>0022-3565</issn><issn>1521-0103</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kE1Lw0AURQdRbK2u3cksLZh2PjKTZBmKWqGgtHUdJvOhKU0mTKZi_ok_18TUrt7lcN97cAC4xWiGMQnnu1r7GSZkhhAOWXgGxpgRHCCM6DkYI0RIQBlnI3DVNLu-E3J6CUaUc57EERuDn7dP4Uoh7d5-FBKm0hdfhW-hNXBzyBtf-IPXCm5dW3tRFpVuoPCQBctWOfvd-hOH9x3cTiFJ4VpLXXvrBvRHpg9wyAu4Pkac9lFUCm60s95WRdW9EVVTW-e1uwYXRuwbfXOcE_D-9LhdLIPV6_PLIl0FEqOEBcoIKqiOUBJSlGgVS8MNz6M4QjqMJUcGY4GiWEhF4jDRuclDyQljRNEkMpJOwHy4K51tGqdNVruiFK7NMMp6x1nvOOscZ4PjbuNu2KgPeanVqf8vlf4CaNp1qw</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Kozell, Laura B</creator><creator>Eshleman, Amy J</creator><creator>Swanson, Tracy L</creator><creator>Bloom, Shelley H</creator><creator>Wolfrum, Katherine M</creator><creator>Schmachtenberg, Jennifer L</creator><creator>Olson, Randall J</creator><creator>Janowsky, Aaron</creator><creator>Abbas, Atheir I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-7080-3509</orcidid></search><sort><creationdate>202304</creationdate><title>Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter</title><author>Kozell, Laura B ; Eshleman, Amy J ; Swanson, Tracy L ; Bloom, Shelley H ; Wolfrum, Katherine M ; Schmachtenberg, Jennifer L ; Olson, Randall J ; Janowsky, Aaron ; Abbas, Atheir I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Hallucinogens</topic><topic>Humans</topic><topic>Receptor, Serotonin, 5-HT2A - metabolism</topic><topic>Receptor, Serotonin, 5-HT2C - metabolism</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Plasma Membrane Transport Proteins</topic><topic>Tryptamines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kozell, Laura B</creatorcontrib><creatorcontrib>Eshleman, Amy J</creatorcontrib><creatorcontrib>Swanson, Tracy L</creatorcontrib><creatorcontrib>Bloom, Shelley H</creatorcontrib><creatorcontrib>Wolfrum, Katherine M</creatorcontrib><creatorcontrib>Schmachtenberg, Jennifer L</creatorcontrib><creatorcontrib>Olson, Randall J</creatorcontrib><creatorcontrib>Janowsky, Aaron</creatorcontrib><creatorcontrib>Abbas, Atheir I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kozell, Laura B</au><au>Eshleman, Amy J</au><au>Swanson, Tracy L</au><au>Bloom, Shelley H</au><au>Wolfrum, Katherine M</au><au>Schmachtenberg, Jennifer L</au><au>Olson, Randall J</au><au>Janowsky, Aaron</au><au>Abbas, Atheir I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2023-04</date><risdate>2023</risdate><volume>385</volume><issue>1</issue><spage>62</spage><epage>75</epage><pages>62-75</pages><issn>0022-3565</issn><eissn>1521-0103</eissn><abstract>Novel psychoactive substances, including synthetic substituted tryptamines, represent a potential public health threat. Additionally, some substituted tryptamines are being studied under medical guidance as potential treatments of psychiatric disorders. Characterizing the basic pharmacology of substituted tryptamines will aid in understanding differences in potential for harm or therapeutic use. Using human embryonic kidney cells stably expressing 5-hydroxytryptamine (5-HT) , 5-HT , and 5-HT receptors (5-HT R, 5-HT R, and 5HT R, respectively) or the serotonin transporter (SERT), we measured affinities, potencies and efficacies of 21 substituted tryptamines. With the exception of two 4-acetoxy compounds, substituted tryptamines exhibited affinities and potencies less than one micromolar at the 5-HT R, the primary target for psychedelic effects. In comparison, half or more exhibited low affinities/potencies at 5-HT R, 5-HT R, and SERT. Sorting by the ratio of 5-HT to 5-HT , 5-HT , or SERT affinity revealed chemical determinants of selectivity. We found that although 4-substituted compounds exhibited affinities that ranged across a factor of 100, they largely exhibited high selectivity for 5-HT Rs versus 5-HT Rs and 5-HT Rs. 5-substituted compounds exhibited high affinities for 5-HT Rs, low affinities for 5-HT Rs, and a range of affinities for 5-HT Rs, resulting in selectivity for 5-HT Rs versus 5-HT Rs but not versus 5-HT Rs. Additionally, a number of psychedelics bound to SERT, with non-ring-substituted tryptamines most consistently exhibiting binding. Interestingly, substituted tryptamines and known psychedelic standards exhibited a broad range of efficacies, which were lower as a class at 5-HT Rs compared with 5-HT Rs and 5-HT Rs. Conversely, coupling efficiency/amplification ratio was highest at 5-HT Rs in comparison with 5-HT Rs and 5-HT Rs. SIGNIFICANCE STATEMENT: Synthetic substituted tryptamines represent both potential public health threats and potential treatments of psychiatric disorders. The substituted tryptamines tested differed in affinities, potencies, and efficacies at 5-hydroxytryptamine (5-HT) , 5-HT , and 5HT receptors and the serotonin transporter (SERT). Several compounds were highly selective for and coupled very efficiently downstream of 5-HT versus 5-HT and 5-HT receptors, and some bound SERT. This basic pharmacology of substituted tryptamines helps us understand the pharmacologic basis of their potential for harm and as therapeutic agents.</abstract><cop>United States</cop><pmid>36669875</pmid><doi>10.1124/jpet.122.001454</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-7080-3509</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2023-04, Vol.385 (1), p.62-75
issn 0022-3565
1521-0103
language eng
recordid cdi_crossref_primary_10_1124_jpet_122_001454
source Medical Journals
subjects Hallucinogens
Humans
Receptor, Serotonin, 5-HT2A - metabolism
Receptor, Serotonin, 5-HT2C - metabolism
Serotonin - metabolism
Serotonin Plasma Membrane Transport Proteins
Tryptamines - pharmacology
title Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT) 2A Receptor (5-HT 2A R), 5-HT 2C R, 5-HT 1A R, and Serotonin Transporter
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A43%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacologic%20Activity%20of%20Substituted%20Tryptamines%20at%205-Hydroxytryptamine%20(5-HT)%202A%20Receptor%20(5-HT%202A%20R),%205-HT%202C%20R,%205-HT%201A%20R,%20and%20Serotonin%20Transporter&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Kozell,%20Laura%20B&rft.date=2023-04&rft.volume=385&rft.issue=1&rft.spage=62&rft.epage=75&rft.pages=62-75&rft.issn=0022-3565&rft.eissn=1521-0103&rft_id=info:doi/10.1124/jpet.122.001454&rft_dat=%3Cpubmed_cross%3E36669875%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1095-dfa3a3e7094309ed8cf6f6b7870e48c60f11a078acd2849ebfb4c62552d397fc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/36669875&rfr_iscdi=true